FDA approves gene therapy for deafness
- The FDA on April 23 approved Regeneron’s Otarmeni, or lunsotogene parvec-cwha, for OTOF-related deafness — the first gene therapy cleared for genetic hearing loss. - In Regeneron’s CHORD trial, 80% met the hearing endpoint by 24 weeks, and 42% later reached normal hearing levels that included whispers. - It opens a new path beyond cochlear implants for a tiny, ultra-rare group — about 50 U.S. newborns yearly.
Gene therapy for deafness has been one of those ideas that sounded obvious and impossibly hard at the same time. If a child is born unable to hear because one broken gene stops the inner ear from sending sound signals, why not replace the gene? The problem was delivery. The ear is tiny, delicate, and hard to reach, and the OTOF gene involved here is too large for the usual single-virus gene therapy package. On April 23, the FDA said yes anyway, approving Regeneron’s Otarmeni for a rare inherited form of profound hearing loss. (fda.gov) ### What exactly got approved? Otarmeni — the brand name for lunsotogene parvec-cwha — is approved for children and adults with severe-to-profound or profound sensorineural hearing loss caused by confirmed mutations in both copies of the OTOF gene. The label is narrow. Patients need preserved outer hair cell function, and they cannot have had a cochlear implant in the same ear being treated. (fda.gov) ### What does OTOF do? OTOF makes otoferlin, a protein inner hair cells need to pass sound information to the auditory nerve. Without it, the ear can detect sound vibrations but fails at the handoff step — basically, the microphone works, but the cable to the speaker (fda.gov)working again. (fda.gov) ### Why was this technically hard? The catch is size. OTOF is too big to fit into the standard single adeno-associated virus payload used in many gene therapies. Otarmeni gets around that by using a dual AAV1 vector system, making it the first dual-AAV gene therapy the FDA has approved. The treatment is given once, surgically, into the cochlea through a syringe, catheter, and infusion pump setup. (fda.gov) ### How well did it work? The headline number is strong for such a small and difficult field. Regeneron says the FDA based accelerated approval on CHORD trial data showing 80% of participants reached or beat the primary hearing endpoint by week 24. With longer follow-(fda.gov)matory portion. (investor.regeneron.com) ### Why is the FDA making such a big deal of this? This was not a routine review. The FDA says approval came 61 days after the biologics license application filing under its Commissioner’s National Priority Voucher pilot, and it tied for the fastest BLA approval in modern FDA(investor.regeneron.com)unusually fast when a rare disease has no disease-modifying treatment. (fda.gov) ### Who is this for in real life? Not many people — but for the families involved, it is enormous. OTOF variants account for only a slice of inherited non-syndromic hearing loss, and reports around the approval put the U.S. population at roughly 50 newborns a year. Be(fda.gov)uage delays compound the damage. (fda.gov) ### Why is “free” such a big part of the story? Because gene therapies usually come with brutal price tags. Regeneron said it will provide Otarmeni free in the U.S., which is almost as headline-worthy as the approval itself. Turns out access is part of the experiment here too — a breakthrough does not change much if the eligible patients cannot actually get it. (investor.regeneron.com) ### Bottom line This is a tiny market and a very specific disease. But it is still a milestone. Otarmeni is the first approved gene therapy for genetic hearing loss, the first approved dual-AAV therapy, and an early proof that some forms of congenital deafness may be biologically reversible, not just managed. (fda.gov)
